Trial Profile
A retrospective study of of anti-IL-5/5R therapy in severe eosinophilic asthma with comorbid bronchiectasis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Feb 2023
Price :
$35
*
At a glance
- Drugs Benralizumab (Primary) ; Mepolizumab (Primary) ; Reslizumab (Primary)
- Indications Asthma; Bronchiectasis
- Focus Therapeutic Use
- 07 Feb 2023 New trial record